Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS) (English, HTML)

View metadata and access the original English HTML file: Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS).

Format

HTML

Access

file-only

Publisher-reported update

2024-05-10

Health Canada carried out a safety review after finding international cases of DRESS suspected of being linked with the use of Uloric (febuxostat). DRESS describes a group of rare, but serious and potentially life-threatening, side effects of a medication, with symptoms such as fever, severe skin rash with swollen face or peeling of the skin over large areas of the body, etc. These reactions usually happen two weeks to two months after starting a medication.

Access original file